Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset.

Literature DB >> 32783250

B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset.

S O'Reilly¹, J van Laar².

Abstract

Entities: Disease

Year: 2020 PMID： 32783250 PMCID： PMC7419925 DOI： 10.1111/cei.13501

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

× No keyword cloud information.

13 in total

1. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.

Authors: Yun Zhang; Ruifang Liang; Chih-Wei Chen; Tatjana Mallano; Clara Dees; Alfiya Distler; Adam Reich; Christina Bergmann; Andreas Ramming; Kolja Gelse; Dirk Mielenz; Oliver Distler; Georg Schett; Jörg H W Distler
Journal: Ann Rheum Dis Date: 2017-05-06 Impact factor: 19.103

2. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.

Authors: Takashi Matsushita; Yasuhito Hamaguchi; Minoru Hasegawa; Kazuhiko Takehara; Manabu Fujimoto
Journal: Rheumatology (Oxford) Date: 2015-09-08 Impact factor: 7.580

3. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.

Authors: Dafna Gladman; William Rigby; Valderilio F Azevedo; Frank Behrens; Ricardo Blanco; Andrzej Kaszuba; Elizabeth Kudlacz; Cunshan Wang; Sujatha Menon; Thijs Hendrikx; Keith S Kanik
Journal: N Engl J Med Date: 2017-10-19 Impact factor: 91.245

4. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Authors: Steven O'Reilly; Marzena Ciechomska; Rachel Cant; Jacob M van Laar
Journal: J Biol Chem Date: 2014-02-18 Impact factor: 5.157

Review 5. Toll-like receptors in mediating pathogenesis in systemic sclerosis.

Authors: L Frasca; R Lande
Journal: Clin Exp Immunol Date: 2020-02-21 Impact factor: 4.330

6. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.

Authors: Satoshi Ebata; Ayumi Yoshizaki; Takemichi Fukasawa; Shunsuke Miura; Takehiro Takahashi; Hayakazu Sumida; Yoshihide Asano; Shinichi Sato
Journal: J Dermatol Date: 2019-09-09 Impact factor: 4.005

7. Generation of a novel CD30⁺ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis.

Authors: K Higashioka; Y Kikushige; M Ayano; Y Kimoto; H Mitoma; M Kikukawa; M Akahoshi; Y Arinobu; T Horiuchi; K Akashi; H Niiro
Journal: Clin Exp Immunol Date: 2020-07-14 Impact factor: 4.330

B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset.

1. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.

2. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.

3. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.

4. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Review 5. Toll-like receptors in mediating pathogenesis in systemic sclerosis.

6. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.

7. Generation of a novel CD30⁺ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis.

8. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.

Review 9. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope.

Review 10. Novel insights into dendritic cells in the pathogenesis of systemic sclerosis.

Review 1. Esophageal Dysfunction in Systemic Sclerosis: An Update.